Michael R. Megna

CIK: 0001464583

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)18 (20.7%)

Position reduction

Option Exercises (M)36 (41.4%)

Derivative conversions

Awards (A)20 (23.0%)

Compensation grants

Other (G, F, J, C, D, …)13 (14.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

KNSA

Kiniksa Pharmaceuticals International, plc

Discretionary Trading P&L

Holdings

Transaction History (87 total)

KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
7.2K shares at avg. $11.97$86K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
3.7K shares at avg. $94.86$351K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
6.8K shares at avg. $92.77$634K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
4.1K shares at avg. $17.76$72K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
3.9K shares at avg. $11.10$44K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Exercise(M)
Direct
4.7K shares at avg. $10.76$50K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
3.1K shares at avg. $96.08$302K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
9.5K shares at avg. $94.20$896K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
1.7K shares at avg. $97.11$164K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
6K shares at avg. $91.87$554K
KNSA
Kiniksa Pharmaceuticals International, plc
Oct 30, 2026
Sale(S)
Direct
5.4K shares at avg. $97.74$523K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 3, 2026
Sale(S)
Direct
4.6K shares at avg. $80.30$369K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Tax Payment(F)
Direct
5.5K shares at avg. $79.28$438K
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Share Option
Direct
14.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
2.4K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Award(A)
Restricted Share Unit
Direct
3.7K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Sep 1, 2026
Exercise(M)
Direct
3.9K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Jul 15, 2026
Award(A)
Direct
279 shares at avg. $33.50$9K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 9, 2026
Sale(S)
Direct
6.6K shares at avg. $46.69$309K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 7, 2026
Exercise(M)
Direct
3.9K shares at avg. $1.00$4K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 7, 2026
Tax Payment(F)
Direct
1.7K shares at avg. $48.94$82K
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Exercise(M)
Direct
7.6K shares-
KNSA
Kiniksa Pharmaceuticals International, plc
Apr 1, 2026
Award(A)
Share Option
Direct
14.6K shares-

		Type	Shares	Price		Ownership
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	7,209	$11.97	$86,292	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	3,705	$94.86	$351,456	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,831	$92.77	$633,712	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	4,065	$17.76	$72,194	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,932	$11.10	$43,645	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	4,689	$10.76	$50,454	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	3,145	$96.08	$302,172	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	9,508	$94.20	$895,654	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	1,691	$97.11	$164,213	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,030	$91.87	$553,976	Direct
Oct 30, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	5,350	$97.74	$522,909	Direct
Sep 3, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	4,600	$80.30	$369,380	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	5,531	$79.28	$438,498	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	14,600	-	-	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,644	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,558	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	2,362	-	$0	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Restricted Share Unit	3,650	-	-	Direct
Sep 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,932	-	$0	Direct
Jul 15, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A)	279	$33.50	$9,347	Direct
Apr 9, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Sale(S)	6,625	$46.69	$309,321	Direct
Apr 7, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	3,932	$1.00	$3,932	Direct
Apr 7, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Tax Payment(F)	1,666	$48.94	$81,534	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Exercise(M)	7,564	-	$0	Direct
Apr 1, 2026	KNSA Kiniksa Pharmaceuticals International, plc	Award(A) Share Option	14,600	-	-	Direct

1-25 of 87 transactions

About Megna Michael R

Megna Michael R (SEC CIK 0001464583) files insider reports with the SEC as CHIEF ACCOUNTING OFFICER of Kiniksa Pharmaceuticals International, plc (KNSA).

Signal8 holds 19 ownership filings by Megna Michael R, all Form 4s, filed between Sep 4, 2024 and Nov 3, 2026. Those filings report 87 transactions, from Jul 15, 2024 to Oct 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Megna Michael R's filings is in LONDON.

Recent filings by Megna Michael R

Oct 30, 2026: Option exercise of KNSA shares (Form 4, code M).
Oct 30, 2026: Open-market sales of KNSA shares (2 lines, Form 4, code S).
Oct 30, 2026: Option exercises of KNSA shares (3 lines, Form 4, code M).
Oct 30, 2026: Open-market sales of KNSA shares (5 lines, Form 4, code S).
Sep 3, 2026: Open-market sale of KNSA shares (Form 4, code S).

Other insiders filing for Kiniksa Pharmaceuticals International, plc (KNSA)

Ragosa Mark, CHIEF FINANCIAL OFFICER
Patel Sanj K, CHAIRMAN & CEO
Paolini John F., CHIEF MEDICAL OFFICER
Moat Ross, CHIEF OPERATING OFFICER
Quart Barry D, Director
Levy Richard S, Director

How to read Form 4 transaction codes